NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ:AGIO) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
At the December 2016 American Society of Hematology meeting, Agios presented new data for its AG-519 molecule, which is in development for treatment of pyruvate kinase deficiency. Agios reported for AG-519 that after the data cut-off, one ongoing serious adverse event of drug related cholestatic hepatitis was reported after a dose of 300 mg.
On December 5, 2016, following this news, Agios stock fell over 12% to close at $49.88. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.